3
May
2022
Dianthus Gets $100m to Take Complement Inhibition to a New Level
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Apr
2022
A Big Opportunity in Obesity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Apr
2022
The Timmerman Traverse for Life Science Cares Is Back, Fighting Poverty
The biotech community has plenty of people willing to work to support vulnerable members of our society. This year, I’m doing what I can to again mobilize the biotech community to fight poverty. I’m happy to announce the Timmerman Traverse for Life Science Cares. It’s a Presidential Traverse hike set for Sept. 11-14, 2022. This expedition builds on the success... Read More
21
Apr
2022
Regeneron Buys Checkmate, Bivalent Vaccine Progress, & a Fitting Acronym
Clinical trialists are always trying to come up with catchy study titles. I’m not a big fan of these acronyms, and try to avoid using them. They’re often forgettable. But this week I saw one that stood out as especially meaningful. Yale University researchers are running a new Long COVID study. It’s called – LISTEN. It stands for Listen to... Read More
19
Apr
2022
Microbiome-based Drug Development: Bernat Olle on The Long Run
Today’s guest on The Long Run is Bernat Olle. Bernat is the CEO of Cambridge, Mass.-based Vedanta Biosciences. The company was founded in 2010 by Puretech Health, in collaboration with a handful of academic founders. At the time, the faster/cheaper tools of DNA sequencing were making it possible for immunologists and microbiologists to gain a much more fine-grained view of... Read More
14
Apr
2022
GSK Acquires Sierra, Cimeio’s Shielded Cell Therapies, & AACR Highlights
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Apr
2022
Versant-backed Cimeio Gets $50M for Shielded Stem Cell Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Mar
2022
LifeMine Snags GSK Deal and $175m to Drive Fungus-Based Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Mar
2022
Structural Biology-Driven Drug Discovery: Ray Stevens on The Long Run
Today’s guest on the Long Run is Ray Stevens. Ray is the CEO of ShouTi. It’s a company that uses advanced structural biology technologies like cryo-EM images, and computational techniques, to discover small molecule drugs. The idea is to come up with orally available medicines that can build off the biological insights gained from protein or peptide drugs, but replace... Read More
10
Mar
2022
Aiming High, With a Team
Climbing Mt. Everest changed my life. The world’s highest mountain required digging deep — physically, mentally, emotionally. That was four years ago. That original climb was a success, raising $340,000 for cancer research at the Fred Hutchinson Cancer Research Center. But what came next meant more. The climb opened my mind to new ways of making a contribution, in addition... Read More
3
Mar
2022
Biotech Takes a Stand
Not long ago, biotech leaders steered clear of commenting on the issues of the day. Politics was limited to certain vested interests like drug pricing, science funding, and FDA regulation. Then came COVID-19 and the racial justice reckoning. Staring these terrible things in the face, people began to think more about their roles in the workplace, and in the community.... Read More
2
Mar
2022
Rondo Raises $67M to Make Bispecific T-cell Engagers for Solid Tumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Feb
2022
Making Clinical Trials More Diverse: Michele Andrasik on The Long Run
Today’s guest on The Long Run is Michele Andrasik. I’m excited to have Michele on the show to talk about an undercovered aspect of the scientific enterprise. Michele is the director of social and behavioral science and community engagement for the HIV Vaccine Trials Network, and COVID-19 Prevention Network. She’s based in Seattle at the Fred Hutchinson Cancer Research Center,... Read More
17
Feb
2022
The Unsung Community Heroes Who Make Biotech Thrive
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Feb
2022
Rethinking the Cell Therapy Business: Derrell Porter of Cellevolve on The Long Run
Today’s guest on The Long Run is Derrell Porter. Derrell is the founder and CEO of San Francisco-based Cellevolve. This is a different kind of biotech startup. Most startups are all about the R&D. Traditionally, many haven’t built up commercial capabilities in the early days for one big reason — they don’t have anything to sell. They have tended to... Read More
10
Feb
2022
Biotech’s Future off The Beaten Path
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Feb
2022
Seismic Gets $101M to Use Machine Learning for Autoimmune Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Feb
2022
The World Waits for Novavax, and an FDA Commissioner
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2022
TR’s 7th Anniversary: Thank You
Timmerman Report is 7 years old today. On Feb. 2, 2015, I rode my bike to the office on a wet Seattle morning and turned on the lights. I thought there was a need for clear, probing, contextual biotech journalism. It was a leap of faith, like any entrepreneurial venture. I couldn’t have predicted 90 percent of what came next.... Read More
1
Feb
2022
Targeting Integrins With Small Molecules: Praveen Tipirneni on The Long Run
Today’s guest on The Long Run is Praveen Tipirneni. Praveen is the CEO of Waltham, Mass.-based Morphic Therapeutic. Morphic Therapeutic is developing oral small molecule drugs aimed at integrin targets. There’s some fascinating biology and computational technology underpinning this work, which I discussed a couple years ago on The Long Run with Morphic scientific founder Tim Springer. Just to review... Read More